Abstract: The clinical efficacy and safety of antiVEGF therapy via intravitreal injection of ranibizumab for wet agerelated macular degeneration have been proved in several clinical trials. So far studies are focus on the therapy schedule which has changed from the early fixed model, PRN model to the stability model and prolongation model recently. The criteria concerns not only visual function, but also other factors such as disease activity, patient’s willingness, medical cost and so on. This article reviews recent clinical trials and summarizes research progress of treatment schedule for ranibizumab therapy in wet agerelated macular degeneration. (Int Rev Ophthalmol, 2014, 38: 73-80)